Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) incidence and mortality are rising, and current treatments have limitations. Novel liver-targeted drug delivery systems have thus emerged as a viable approach for HCC treatment, and combining two or more synergistic drugs represents an effective therapeutic strategy. In this study, the optimal synergistic ratio of bufalin (BF) and quercetin (QUE) was determined by MTT assay and combination index (CI) analysis to be 4:3 (mass ratio). A conjugate of Angelica sinensis polysaccharide (ASP) and ursodeoxycholic acid (UDCA) was synthesized as a carrier, and novel pH-responsive hepatic-targeted nanoparticles co-delivering BF and QUE at the optimal ratio (BF-QUE/ASP-UDCA NPs) were successfully fabricated, with a mean diameter of 166.57 ± 2.7 nm and a zeta potential of -8.83 ± 0.109 mV. The NPs exhibited good stability, pH-dependent release, enhanced cellular uptake, and higher inhibition rates. Importantly, BF, QUE, and UDCA displayed synergistic anti‑HCC effects. In H22 tumor-bearing mice, the BF-QUE/ASP-UDCA NPs group achieved a tumor inhibition rate of 72.24% and could exert antitumor activity by modulating immune function in mice. Collectively, BF‑QUE/ASP‑UDCA NPs show liver targeting and synergistic anti‑HCC efficacy, making them a promising nanocarrier system for liver tumor therapy.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: